Analyse
31. Aug. 2026•1 Min. Lesezeit
Hanmi Pharm Q2 earnings buoyed by one‑off Lilly tech transfer payment, core sales lag
Hanmi Pharm's Q2 results show strong growth due to a KRW 112.9 bn upfront from Eli Lilly for GLP‑2 candidate sonepegLutide, but analysts say core sales remain weak.
Analyse
30. Aug. 2026•1 Min. Lesezeit
Celltrion Beats Q2 Market Expectations, Analysts Raise Target Prices
Celltrion reported Q2 revenue of 1.3 trillion KRW and operating profit of 430 billion KRW, surpassing consensus estimates, prompting analysts to lift target prices.